Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Profit After Tax (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Profit After Tax for 9 consecutive years, with -$44.4 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax fell 133.71% to -$44.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$130.1 million through Dec 2025, down 147.29% year-over-year, with the annual reading at -$130.1 million for FY2025, 147.29% down from the prior year.
  • Profit After Tax hit -$44.4 million in Q4 2025 for Protagonist Therapeutics, down from -$39.3 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $207.3 million in Q1 2024 to a low of -$44.4 million in Q4 2025.
  • Historically, Profit After Tax has averaged -$9.3 million across 5 years, with a median of -$33.5 million in 2023.
  • Biggest five-year swings in Profit After Tax: crashed 335.45% in 2021 and later soared 714.8% in 2024.
  • Year by year, Profit After Tax stood at -$36.9 million in 2021, then grew by 7.35% to -$34.2 million in 2022, then surged by 179.94% to $27.3 million in 2023, then soared by 381.7% to $131.7 million in 2024, then tumbled by 133.71% to -$44.4 million in 2025.
  • Business Quant data shows Profit After Tax for PTGX at -$44.4 million in Q4 2025, -$39.3 million in Q3 2025, and -$34.8 million in Q2 2025.